- Diseases
- Acoustic Neuroma (14)
- Adrenal Gland Tumor (24)
- Anal Cancer (66)
- Anemia (2)
- Appendix Cancer (16)
- Bile Duct Cancer (26)
- Bladder Cancer (68)
- Brain Metastases (28)
- Brain Tumor (230)
- Breast Cancer (718)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (154)
- Colon Cancer (164)
- Colorectal Cancer (110)
- Endocrine Tumor (4)
- Esophageal Cancer (42)
- Eye Cancer (36)
- Fallopian Tube Cancer (6)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (6)
- Kidney Cancer (124)
- Leukemia (344)
- Liver Cancer (50)
- Lung Cancer (288)
- Lymphoma (284)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (98)
- Myelodysplastic Syndrome (60)
- Myeloproliferative Neoplasm (4)
- Neuroendocrine Tumors (16)
- Oral Cancer (100)
- Ovarian Cancer (170)
- Pancreatic Cancer (164)
- Parathyroid Disease (2)
- Penile Cancer (14)
- Pituitary Tumor (6)
- Prostate Cancer (144)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (236)
- Skin Cancer (296)
- Skull Base Tumors (56)
- Spinal Tumor (12)
- Stomach Cancer (60)
- Testicular Cancer (28)
- Throat Cancer (90)
- Thymoma (6)
- Thyroid Cancer (98)
- Tonsil Cancer (30)
- Uterine Cancer (78)
- Vaginal Cancer (14)
- Vulvar Cancer (18)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (20)
- Advance Care Planning (10)
- Biostatistics (2)
- Blood Donation (18)
- Bone Health (8)
- COVID-19 (362)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (626)
- Complementary Integrative Medicine (24)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (230)
- Epigenetics (6)
- Fertility (64)
- Follow-up Guidelines (2)
- Health Disparities (14)
- Hereditary Cancer Syndromes (124)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (118)
- Molecular Diagnostics (8)
- Pain Management (62)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (896)
- Research (390)
- Second Opinion (74)
- Sexuality (16)
- Side Effects (604)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (404)
- Survivorship (322)
- Symptoms (184)
- Treatment (1774)
MD Anderson receives $19.1 million in CPRIT awards
BY Ron Gilmore
2 minute read | Published September 07, 2016
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on September 07, 2016

MD Anderson Cancer Center has been awarded $19.1 million in research grants in the most recent round of funding from the Cancer Prevention and Research Institute of Texas (CPRIT). Sixty-three percent of funds awarded for Multi-Investigator Research Awards went to MD Anderson faculty as well as 20 percent of funds awarded for recruitment, reflecting the importance of the institution’s research and impact of its world-renowned cancer researchers and star recruitment candidates
Across Texas institutions, CPRIT awarded a total of $61.5 million in 26 new grants. MD Anderson received $17.1 million for research, which will fund novel studies in breast cancer and leukemia as well as basic science investigation of DNA repair and cancer therapy, and $2 million in recruitment. A listing of individual awards can be found below.
“We are thankful to the State of Texas for ensuring novel and life-saving cancer research continues. CPRIT plays an important role in helping us accomplish our mission to end cancer,” said MD Anderson President Ronald DePinho, M.D. “CPRIT funding also is vital to our recruitment of some of the nation’s brightest talent in cancer research and care. I congratulate our investigators recognized through this funding and applaud the ongoing scientific and clinical progress of our entire faculty.”
MD Anderson research awards include the following:
- DNA-protein crosslink repair pathways and cancer therapy (Junjie Chen, Ph.D., chair of Experimental Radiation Oncology) – $5,101,316
- Acute myeloid leukemia in the immunosuppressed microenvironment (Michael Andreef, M.D., Ph.D., professor of Leukemia) – $6,000,000
- A randomized clinical trial platform with translational studies to overcome resistance in triple negative breast cancer (William Symmans, M.D., professor of Pathology) – $5,997,677.
Beginning operations in 2009, CPRIT has to date awarded $1.64 billion in grants to Texas researchers, institutions and organizations. CPRIT provides funding through its academic research, prevention and product development research programs. Programs made possible with CPRIT funding have reached all 254 counties of the state, brought more than 110 distinguished researchers to Texas, advanced scientific and clinical knowledge, and provided more than 3 million life-saving education, training, prevention and early detection services to Texans.